Stock page
Apimeds Pharmaceuticals Us Inc (APUS)
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Quote snapshot
$1.5135
Daily change: —
ExchangeAMEX
Updated2026-05-09T04:29:51.737448Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|